In a challenging market environment, shares of Eliem Therapeutics, Inc. (CLYM) have reached a 52-week low, dipping to $1.5. According to InvestingPro data, the company maintains a strong financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback